Janney Montgomery Scott LLC Invests $694,000 in Charles River Laboratories Intl. Inc (CRL)

Janney Montgomery Scott LLC purchased a new stake in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 6,427 shares of the medical research company’s stock, valued at approximately $694,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Davidson Kempner Capital Management LP boosted its stake in shares of Charles River Laboratories Intl. by 62.5% in the third quarter. Davidson Kempner Capital Management LP now owns 162,500 shares of the medical research company’s stock valued at $17,553,000 after purchasing an additional 62,500 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Charles River Laboratories Intl. by 69.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 548 shares during the period. Cubist Systematic Strategies LLC boosted its stake in shares of Charles River Laboratories Intl. by 18.5% in the third quarter. Cubist Systematic Strategies LLC now owns 7,431 shares of the medical research company’s stock valued at $803,000 after purchasing an additional 1,159 shares during the period. Zions Bancorporation purchased a new position in shares of Charles River Laboratories Intl. in the third quarter valued at approximately $212,000. Finally, Earnest Partners LLC boosted its stake in shares of Charles River Laboratories Intl. by 8.6% in the third quarter. Earnest Partners LLC now owns 262,262 shares of the medical research company’s stock valued at $28,330,000 after purchasing an additional 20,683 shares during the period. Institutional investors and hedge funds own 95.80% of the company’s stock.

Charles River Laboratories Intl. Inc (CRL) opened at $108.51 on Monday. The company has a market cap of $5,140.00, a price-to-earnings ratio of 26.53, a PEG ratio of 1.73 and a beta of 0.89. Charles River Laboratories Intl. Inc has a 1-year low of $74.46 and a 1-year high of $119.05. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.88 and a quick ratio of 1.62.

Charles River Laboratories Intl. (NYSE:CRL) last announced its earnings results on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. Charles River Laboratories Intl. had a net margin of 11.42% and a return on equity of 21.22%. The company’s quarterly revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 EPS. analysts predict that Charles River Laboratories Intl. Inc will post 5.14 earnings per share for the current fiscal year.

A number of brokerages recently issued reports on CRL. Robert W. Baird set a $117.00 price target on shares of Charles River Laboratories Intl. and gave the stock a “buy” rating in a research note on Monday, November 13th. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price target for the company in a research note on Tuesday, October 24th. Bank of America decreased their price target on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, November 10th. Jefferies Group lifted their price target on shares of Charles River Laboratories Intl. from $120.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, October 9th. Finally, Royal Bank of Canada began coverage on shares of Charles River Laboratories Intl. in a research note on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 price target for the company. Six investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Charles River Laboratories Intl. has a consensus rating of “Buy” and a consensus target price of $110.21.

In other Charles River Laboratories Intl. news, insider Davide Molho sold 6,165 shares of the business’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $110.00, for a total value of $678,150.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director C Richard Reese sold 10,227 shares of the business’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $102.40, for a total transaction of $1,047,244.80. Following the completion of the transaction, the director now directly owns 51,444 shares in the company, valued at $5,267,865.60. The disclosure for this sale can be found here. Over the last three months, insiders acquired 10,500 shares of company stock worth $2,885 and sold 1,056,776 shares worth $2,011,952. Insiders own 2.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2017/12/25/janney-montgomery-scott-llc-invests-694000-in-charles-river-laboratories-intl-inc-crl.html.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit